Patricia Pozo-Rosich
Overview
Explore the profile of Patricia Pozo-Rosich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
3315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Membrilla J, Alpuente A, Gomez-Dabo L, Raul G, Marino E, Diaz-de-Teran J, et al.
Eur J Neurol
. 2024 Sep;
31(12):e16484.
PMID: 39287050
Background And Purpose: Patients presenting at the emergency room (ER) with headache often encounter a hostile atmosphere and experience delays in diagnosis and treatment. The aim of this study was...
12.
Puledda F, Sacco S, Diener H, Ashina M, Al-Khazali H, Ashina S, et al.
Cephalalgia
. 2024 Sep;
44(9):3331024241269735.
PMID: 39262214
No abstract available.
13.
Ihara K, Casillo F, Dahshan A, Genc H, Jusupova A, Karbozova K, et al.
Cephalalgia
. 2024 Sep;
44(9):3331024241281518.
PMID: 39256924
Background: The term 'precision medicine' encompasses strategies to optimize diagnosis and outcome prediction and to tailor treatment for individual patients, in consideration of their unique characteristics. The greater availability of...
14.
Peres M, Sacco S, Pozo-Rosich P, Tassorelli C, Ahmed F, Burstein R, et al.
Cephalalgia
. 2024 Aug;
44(8):3331024241267309.
PMID: 39197864
The Global Burden of Disease (GBD) study is pivotal in shaping health policies by providing comprehensive data on mortality and disability. An updated GBD2021 analysis, published in on 14 March...
15.
Pozo-Rosich P, Alpuente A, Silberstein S, Burstein R
Nat Rev Neurol
. 2024 Aug;
20(9):555-568.
PMID: 39160284
OnabotulinumtoxinA (BTX-A) was first linked to beneficial effects in migraine 25 years ago and was approved by the FDA for preventive treatment of chronic migraine in 2010. The treatment has...
16.
Schwedt T, Pradhan A, Oshinsky M, Brin M, Rosen H, Lalvani N, et al.
Headache
. 2024 Aug;
64(8):912-930.
PMID: 39149968
Objective: To identify and disseminate research priorities for the headache field that should be areas of research focus during the next 10 years. Background: Establishing research priorities helps focus and...
17.
Puledda F, Sacco S, Diener H, Ashina M, Al-Khazali H, Ashina S, et al.
Cephalalgia
. 2024 Aug;
44(8):3331024241252666.
PMID: 39133176
Background: In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of...
18.
Navarro-Perez M, Gonzalez-Quintanilla V, Munoz-Vendrell A, Madrigal E, Alpuente A, Latorre G, et al.
Front Neurol
. 2024 Jun;
15:1417831.
PMID: 38938776
Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine...
19.
Gomez-Dabo L, Caronna E, Mas-de-Les-Valls R, Gallardo V, Alpuente A, Torres-Ferrus M, et al.
Toxins (Basel)
. 2024 May;
16(5).
PMID: 38787073
Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature...
20.
Caronna E, Gallardo V, Egeo G, Vazquez M, Castellanos C, Membrilla J, et al.
J Neurol Neurosurg Psychiatry
. 2024 May;
95(10):927-937.
PMID: 38777579
Background: Anti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike and many countries have reimbursement policies, which hinder treatments to those...